Katie Ellias

Director at Veralox Therapeutics

Katie Ellias joined the T1D Fund in July 2018 as a Managing Director from Endeavour Vision, a Geneva-based growth stage venture fund, where she focused on medical devices and digital health as Senior Investment Director. She was previously Principal at Sofinnova Partners, Paris, a leading early stage life sciences fund, investing in medical technologies. She served as Board Observer for ReCor Medical (sold to Otsuka Holdings), CorWave, Shockwave Medical (NASDAQ: SWAV), RefleXion Medical, Pixium Vision (PIX.PA), and MD Start, a medical device accelerator. Katie holds a MBA in Healthcare Management from the Wharton School at the University of Pennsylvania and a BA cum laude in International Relations and Political Science from Yale University.

Timeline

  • Director

    Current role